Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome

Seminars in Immunology

Volumn 23, Issue 1, 2011, Pages 50-57

  Hashimoto, Daigo ^a   Merad Miriam, M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Delayed donor lymphocyte infusion; GVHD; GVT; Host DC vaccine; Host macrophages

Indexed keywords

CD103 ANTIGEN; DENDRITIC CELL VACCINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; CD8+ T LYMPHOCYTE; CELL SUBPOPULATION; CROSS PRESENTATION; DENDRITIC CELL; GRAFT VERSUS HOST REACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LANGERHANS CELL; LYMPHOID ORGAN; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TARGET CELL; TREATMENT OUTCOME;

ANIMALS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; MACROPHAGES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79952452300     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2011.01.005     Document Type: Review

References (112)

1. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
2. Hambach L., Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 2005, 17:202-210.
3. Shlomchik W.D. Antigen presentation in graft-vs.-host disease. Exp Hematol 2003, 31:1187-1197.
4. Baron F., Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol 2004, 26:71-94.
5. Burroughs L., Storb R. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. Curr Opin Hematol 2005, 12:45-54.
6. Deeg H.J., Sandmaier B.M. Who is fit for allogeneic transplantation?. Blood 2010.
7. Mielcarek M., Martin P.J., Leisenring W., Flowers M.E., Maloney D.G., Sandmaier B.M., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
8. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 1996, 8:75-81.
9. Murata M., Warren E.H., Riddell S.R. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003, 197:1279-1289.
10. Goulmy E. Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol 2006, 67:433-438.
11. Spencer C.T., Gilchuk P., Dragovic S.M., Joyce S. Minor histocompatibility antigens: presentation principles, recognition logic and the potential for a healing hand. Curr Opin Organ Transplant 2010, 15:512-525.
12. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., Turka L.A. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001, 166:973-981.
13. Fontaine P., Roy-Proulx G., Knafo L., Baron C., Roy D.C., Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001, 7:789-794.
14. Dickinson A.M., Wang X.N., Sviland L., Vyth-Dreese F.A., Jackson G.H., Schumacher T.N., et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002, 8:410-414.
15. Asakura S., Hashimoto D., Takashima S., Sugiyama H., Maeda Y., Akashi K., et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest 2010, 120:2370-2378.
16. Jenq R.R., van den Brink M.R.M. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010, 10:213-221.
17. Li M., Sun K., Welniak L.A., Murphy W.J. Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Exp Opin Pharmacother 2008, 9:2305-2316.
18. Ferrara J., Levine J., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009.
19. Shulman H.M., Sullivan K.M., Weiden P.L., McDonald G.B., Striker G.E., Sale G.E., et al. Chronic graft-versus-host syndrome in man, a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
20. Sakoda Y., Hashimoto D., Asakura S., Takeuchi K., Harada M., Tanimoto M., et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 2007, 109:1756-1764.
21. Korngold R., Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice, prevention by removing mature T cells from marrow. J Exp Med 1978, 148:1687-1698.
22. Kolb H.J., Rieder I., Rodt H., Netzel B., Grosse-Wilde H., Scholz S., et al. Antilymphocytic antibodies and marrow transplantation. VI. Graft-versus-host tolerance in DLA-incompatible dogs after in vitro treatment of bone marrow with absorbed antithymocyte globulin. Transplantation 1979, 27:242-245.
23. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
24. Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300:1068-1073.
25. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529-1533.
26. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
27. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
28. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
29. Kolb H.J., Schmid C., Barrett A.J., Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004, 103:767-776.
30. den Haan J.M., Sherman N.E., Blokland E., Huczko E., Koning F., Drijfhout J.W., et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995, 268:1476-1480.
31. Rotzschke O., Falk K., Wallny H.J., Faath S., Rammensee H.G. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 1990, 249:283-287.
32. den Haan J.M., Meadows L.M., Wang W., Pool J., Blokland E., Bishop T.L., et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998, 279:1054-1057.
33. Bleakley M., Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004, 4:371-380.
34. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004, 22:1136-1151.
35. Chakraverty R., Eom H.-S., Sachs J., Buchli J., Cotter P., Hsu R., et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 2006, 108:2106-2113.
36. Johnson B.D., Truitt R.L. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995, 85:3302-3312.
37. Mackinnon S., Papadopoulos E.B., Carabasi M.H., Reich L., Collins N.H., Boulad F., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268.
38. Reddy P., Negrin R., Hill G. Mouse models of bone marrow transplantation. Biol Blood Marrow Transplant 2008, 14:129-135.
39. Zhang Y., Louboutin J.-P., Zhu J., Rivera A.J., Emerson S.G. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest 2002, 109:1335-1344.
40. Teshima T., Ordemann R., Reddy P., Gagin S., Liu C., Cooke K.R., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 6:575-581.
41. Matte C.C., Liu J., Cormier J., Anderson B.E., Athanasiadis I., Jain D., et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004, 10:987-992.
42. Shlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
43. Markey K.A., Banovic T., Kuns R.D., Olver S.D., Don A.L.J., Raffelt N.C., et al. Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood 2009, 113:5644-5649.
44. Anderson B.E., McNiff J.M., Jain D., Blazar B.R., Shlomchik W.D., Shlomchik M.J. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 2005, 105:2227-2234.
45. Duffner U.A., Maeda Y., Cooke K.R., Reddy P., Ordemann R., Liu C., et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004, 172:7393-7398.
46. Xia G., Truitt R.L., Johnson B.D. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 2006, 12:397-407.
47. Koyama M., Hashimoto D., Aoyama K., Matsuoka K.-I., Karube K., Niiro H., et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood 2009, 113:2088-2095.
48. Hadeiba H., Sato T., Habtezion A., Oderup C., Pan J., Butcher E.C. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat Immunol 2008, 9:1253-1260.
49. Kolb H.J., Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997, 9:139-145.
50. Schroeder M.L. Transfusion-associated graft-versus-host disease. Br J Haematol 2002, 117:275-287.
51. Reddy P., Maeda Y., Liu C., Krijanovski O.I., Korngold R., Ferrara J.L. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005, 11:1244-1249.
52. Mapara M.Y., Kim Y.M., Wang S.P., Bronson R., Sachs D.H., Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002, 100:1903-1909.
53. Chakraverty R., Cote D., Buchli J., Cotter P., Hsu R., Zhao G., et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 2006, 203:2021-2031.
54. Klangsinsirikul P., Carter G.I., Byrne J.L., Hale G., Russell N.H. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002, 99:2586-2591.
55. Auffermann-Gretzinger S., Lossos I.S., Vayntrub T.A., Leong W., Grumet F.C., Blume K.G., et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002, 99:1442-1448.
56. Helft J., Ginhoux F., Bogunovic M., Merad M. Origin and functional heterogeneity of non-lymphoid tissue dendritic cells in mice. Immunol Rev 2010, 234:55-75.
57. Hildner K., Edelson B.T., Purtha W.E., Diamond M., Matsushita H., Kohyama M., et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008, 322:1097-1100.
58. Stagg A.J., Kamm M.A., Knight S.C. Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immunol 2002, 32:1445-1454.
59. Mora J.R., Cheng G., Picarella D., Briskin M., Buchanan N., von Andrian U.H. Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J Exp Med 2005, 201:303-316.
60. Cyster J.G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005, 23:127-159.
61. Kim T.D., Terwey T.H., Zakrzewski J.L., Suh D., Kochman A.A., Chen M.E., et al. Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood 2008, 111:2929-2940.
62. Collin M.P., Hart D.N.J., Jackson G.H., Cook G., Cavet J., Mackinnon S., et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med 2006, 203:27-33.
63. Bogunovic M., Ginhoux F., Wagers A., Loubeau M., Isola L.M., Lubrano L., et al. Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men. J Exp Med 2006, 203:2627-2638.
64. Merad M., Manz M.G., Karsunky H., Wagers A., Peters W., Charo I., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002, 3:1135-1141.
65. Merad M., Hoffmann P., Ranheim E., Slaymaker S., Manz M.G., Lira S.A., et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004, 10:510-517.
66. Li H., Kaplan D.H., Matte-Martone C., Tan H.S., Venkatesan S., Johnson K., et al. Langerhans cells are not required for graft-versus-host disease. Blood 2010.
67. Durakovic N., Bezak K.B., Skarica M., Radojcic V., Fuchs E.J., Murphy G.F., et al. Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol 2006, 177:4414-4425.
68. Perreault C., Pelletier M., Belanger R., Boileau J., Bonny Y., David M., et al. Persistence of host Langerhans cells following allogeneic bone marrow transplantation: possible relationship with acute graft-versus-host disease. Br J Haematol 1985, 60:253-260.
69. Kornblit B., Masmas T., Petersen S.L., Madsen H.O., Heilmann C., Schejbel L., et al. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:239-252.
70. Yujiri T., Tagami K., Tanaka Y., Mitani N., Nakamura Y., Ariyoshi K., et al. Increased serum levels of high-mobility group box 1 protein in patients who developed acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2010, 85:366-367.
71. Antin J.H., Weisdorf D., Neuberg D., Nicklow R., Clouthier S., Lee S.J., et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002, 100:3479-3482.
72. Gerbitz A., Schultz M., Wilke A., Linde H.J., Scholmerich J., Andreesen R., et al. Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood 2004, 103:4365-4367.
73. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003, 278:8869-8872.
74. Penack O., Smith O.M., Cunningham-Bussel A., Liu X., Rao U., Yim N., et al. NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med 2009, 206:2101-2110.
75. Yang Z., Fuss I.J., Watanabe T., Asano N., Davey M.P., Rosenbaum J.T., et al. NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology 2007, 133:1510-1521.
76. Watanabe T., Kitani A., Murray P.J., Wakatsuki Y., Fuss I.J., Strober W. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006, 25:473-485.
77. Watanabe T., Kitani A., Murray P.J., Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004, 5:800-808.
78. Watanabe T., Asano N., Murray P.J., Ozato K., Tailor P., Fuss I.J., et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008, 118:545-559.
79. Penack O., Holler E., van den Brink M.R. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood 2010, 115:1865-1872.
80. Bromberg J.S., Heeger P.S., Li X.C. Evolving paradigms that determine the fate of an allograft. Am J Transplant 2010, 10:1143-1148.
81. Lalli P.N., Strainic M.G., Yang M., Lin F., Medof M.E., Heeger P.S. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 2008, 112:1759-1766.
82. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., Ferrara J.L. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90:3204-3213.
83. Zhang Y., Shlomchik W.D., Joe G., Louboutin J.P., Zhu J., Rivera A., et al. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol 2002, 169:7111-7118.
84. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
85. Allavena P., Sica A., Garlanda C., Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008, 222:155-161.
86. Krenger W., Falzarano G., Delmonte J., Snyder K.M., Byon J.C., Ferrara J.L. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 1996, 88:1113-1121.
87. Drobyski W.R., Keever C.A., Hanson G.A., McAuliffe T., Griffith O.W. Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival, and impaired alloengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation. Blood 1994, 84:2363-2373.
88. Jasperson L.K., Bucher C., Panoskaltsis-Mortari A., Mellor A.L., Munn D.H., Blazar B.R. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 2009, 114:5062-5070.
89. Banovic T., MacDonald K.P., Morris E.S., Rowe V., Kuns R., Don A., et al. TGF-beta in allogeneic stem cell transplantation: friend or foe?. Blood 2005, 106:2206-2214.
90. Blazar B.R., Carreno B.M., Panoskaltsis-Mortari A., Carter L., Iwai Y., Yagita H., et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 2003, 171:1272-1277.
91. Lee Y.-R., Yang I.-H., Lee Y.-H., Im S.-A., Song S., Li H., et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005, 105:3951-3955.
92. Mehling A., Grabbe S., Voskort M., Schwarz T., Luger T.A., Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000, 165:2374-2381.
93. Piemonti L., Monti P., Allavena P., Sironi M., Soldini L., Leone B.E., et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999, 162:6473-6481.
94. Wilson J., Cullup H., Lourie R., Sheng Y., Palkova A., Radford K.J., et al. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med 2009, 206:387-398.
95. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
96. Olson J.A., Leveson-Gower D.B., Gill S., Baker J., Beilhack A., Negrin R.S. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010, 115:4293-4301.
97. Karsunky H., Merad M., Cozzio A., Weissman I.L., Manz M.G. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 2003, 198:305-313.
98. Levis M., Small D. FLT3 tyrosine kinase inhibitors. Int J Hematol 2005, 82:100-107.
99. Whartenby K.A., Calabresi P.A., McCadden E., Nguyen B., Kardian D., Wang T., et al. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci USA 2005, 102:16741-16746.
100. Sato K., Yamashita N., Baba M., Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 2003, 101:3581-3589.
101. Sato K., Yamashita N., Yamashita N., Baba M., Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003, 18:367-379.
102. Reddy P., Sun Y., Toubai T., Duran-Struuck R., Clouthier S.G., Weisiger E., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008, 118:2562-2573.
103. Chorny A., Gonzalez-Rey E., Fernandez-Martin A., Ganea D., Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 2006, 107:3787-3794.
104. Cecchini M.G., Dominguez M.G., Mocci S., Wetterwald A., Felix R., Fleisch H., et al. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development 1994, 120:1357-1372.
105. Muranski P., Boni A., Wrzesinski C., Citrin D.E., Rosenberg S.A., Childs R., et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?. Nat Clin Pract Oncol 2006, 3:668-681.
106. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
107. Jenq R.R., King C.G., Volk C., Suh D., Smith O.M., Rao U.K., et al. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood 2009, 113:1574-1580.
108. Perales M.-A., Diab A., Cohen A.D., Huggins D.W., Guevara-Patiño J.A., Hubbard V.M., et al. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. J Immunol 2006, 177:4159-4167.
109. Teshima T., Mach N., Hill G.R., Pan L., Gillessen S., Dranoff G., et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 2001, 61:162-171.
110. Ho V., Vanneman M., Kim H., Sasada T., Kang Y., Pasek M., et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 2009.
111. Barrett A.J., Mavroudis D., Tisdale J., Molldrem J., Clave E., Dunbar C., et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998, 21:543-551.
112. Peggs K.S., Thomson K., Hart D.P., Geary J., Morris E.C., Yong K., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004, 103:1548-1556.